A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
Ther Adv Med Oncol
; 14: 17588359221142786, 2022.
Article
de En
| MEDLINE
| ID: mdl-36570411
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Type d'étude:
Clinical_trials
/
Observational_studies
Langue:
En
Journal:
Ther Adv Med Oncol
Année:
2022
Type de document:
Article
Pays d'affiliation:
Japon
Pays de publication:
Royaume-Uni